The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Key Takeaways A new HIV shot taken twice a year was nearly 100% effective in trialsGlobal funding cuts could limit access to ...

A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The U.S. Food and Drug Administration this week approved Gilead Sciences’ twice-a-year shot, lenacapvir, to prevent HIV, Gilead announced on Wednesday, June 18. It is the first and only long-acting ...